Sign In
Last checked at 
6 Aug 2024 16:00
Syncona Limited
Result of Annual General Meeting
6 August 2024
At the Annual General Meeting of Syncona Limited (the "Company") held today, all Resolutions as set out in the 'Notice of the 2024 Annual General Meeting' dated 3 July 2024 sent to shareholders of the Company (the "Notice") were duly passed.
Resolutions 1 to 12 were proposed as Ordinary Resolutions. Resolution 13 was proposed as a Special Resolution and Resolution 14 was proposed as an Extraordinary Resolution.
Details of the proxy voting results, which should be read alongside the Notice, are noted below:
No | Resolution | For | Discretion | Against | Abstain (withheld) | |
1 | Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2024, together with the Reports of the Directors and Auditors therein | 487,893,906 (99.99%) | (0) (0%) | 8,329 (0.01%) | 516,479
| |
2 | Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors | 477,577,926 (99.98%) | (0) (0%) | 71,702 (0.02%) | 10,769,086
| |
3 | Authorise the Directors to determine the remuneration of the Auditors | 477,634,135 (99.99%) | (0) (0%) | 21,314 (0.01%) | 10,763,265
| |
4 | Re-elect Melanie Gee as a Director | 485,153,484 (99.44%) | (0) (0%) | 2,748,702 (0.56%) | 516,528
| |
5 | Re-elect Julie Cherrington as a Director | 487,856,391 (99.99%) | (0) (0%) | 45,795 (0.01%) | 516,528
| |
6 | Re-elect Cristina Csimma as a Director | 487,826,744 (99.98%) | (0) (0%) | 75,442 (0.02%) | 516,528
| |
7 | Re-elect Virginia Holmes as a Director | 485,146,832 (99.44%) | (0) (0%) | 2,755,354 (0.56%) | 516,528
| |
8 | Re-elect Robert Hutchinson as a Director | 485,091,732 (99.42%) | (0) (0%) | 2,808,954 (0.58%) | 518,028
| |
9 | Re-elect Kemal Malik as a Director | 485,094,236 (99.42%) | (0) (0%) | 2,806,450 (0.58%) | 518,028
| |
10 | Re-elect Gian Piero Reverberi as a Director | 485,095,482 (99.42%) | (0) (0%) | 2,806,704 (0.58%) | 516,528
| |
11 | Approve the report on implementation of the Remuneration Policy for Non-Executive Directors | 487,781,294 (99.97%) | (0) (0%) | 123,008 (0.03%) | 514,412
| |
12 | Authority to allot and issue shares, as set out in the Notice | 475,216,648 (99.84%) | (0) (0%) | 784,717 (0.16%) | 12,417,349
| |
13 | Authorise the Company to purchase its own shares, as set out in the Notice | 487,879,475 (99.99%) | (0) (0%) | 27,221 (0.01%) | 512,018
| |
14 | Disapply pre-emption rights, as set out in the Notice | 469,084,312 (98.55%) | (0) (0%) | 6,914,778 (1.45%) | 12,419,624
| |
A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.
In accordance with the UK Listing Rule 6.4.2R, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions can be found in the Notice, a copy of which is available on the Company's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/.
Enquiries
Syncona LimitedNatalie Garland-Collins / Fergus Witt
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona:
Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.
We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.
Follow the stocks
